Warning letter
Formulife, Inc.: warning letter of Jun 17, 2013
FDA warning letter 382320 · Dallas District Office
Key facts
| Reference number | 382320 |
|---|---|
| Company | Formulife, Inc. |
| Subject | Unapproved New Drug/Adulterated/Misbranded |
| Issue date | Jun 17, 2013 |
| Posted date | Jun 17, 2013 |
| Issuing office | Dallas District Office |
| Product type | Food/Cosmetics |
| CFR sections cited | 101.36, 101.4(h)(1), 101.4(g), 101.9(c)(8)(iii), 101.36(b)(2)(i), 101.36(b)(3)(ii), 101.36(c)(1), 101.9(c), 101.36(c)(2), 101 |
| Inspection city | Allen |
| Inspection ZIP | 75002 |
| Inspection start date | Aug 1, 2012 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: